Europe’s Own Magnificent Seven
Ben Laidler | Feb 28, 2024 08:07
CONCENTRATION: US tech stock leadership and rising stock concentration are being echoed in Europe. It’s much smaller ‘magnificent 7’ tech stocks have led European performance (see chart) and potentially benefitted from a scarcity valuation premium. Whilst the broader-mix of quality-growth ‘GRANNNOLAS’S’ that are Europe’s equivalent of US big-tech have driven recent performance. They are now a quarter of the Stoxx 600 index, and trade at a similarly big local valuation premium. We see a broadening of performance as the year progresses. Into smaller, more cyclical, and cheaper segments most sensitive to lower interest rates and GDP recovery.
‘MAGNIFICENT 7’: We created a basket of Europe’ seven largest tech stocks. They’ve healthily outperformed the Stoxx 600 but lagged US peers. They have a similar 30x fwd. P/E, but lower profitability and growth. And a fraction of the US’s $12 trillion market value at under $1 trillion. They are Netherland’s ASML (AS:ASML), ADYEN (ADYEN.NV), Germany’s SAP (SAP), Infineon (IFX.DE), France’s STMicro (STM.US), Capgemini (CAP.PA), and UK’s RELX (REL.L). The tech and communications sectors are 11% the European market vs 39% in the US. But benefit from a scarcity premium. With UK tech stocks, for example, the only sector at a premium to US.
‘GRANNNOLAS’S’: This acronym was coined by Goldman Sachs (NYSE:GS) out of 11 of Europe’s biggest stocks. They have similarly driven market performance, making up half Stoxx 600 gains the past year. And dominating the index, with a 25% weight only a little under big tech in the S&P 500. And a similar local premium 21x fwd. P/E valuation. But less growth and profitability and a broader sector base. The eleven are Switzerland’s Nestle (NESN.ZU), Roche (LON:0QQ6) (ROG.ZU), Novartis (LON:0QLR) (NVS), UK’s Glaxo (GSK (LON:GSK).L), AstraZeneca (NASDAQ:AZN.L), France’s LVMH (EPA:LVMH) (MC.PA), L’Oreal (OR.PA), Denmark’s Novo-Nordisk (NVO), Germany’s SAP (SAP), Netherlands’ ASML (ASML).
Get The App
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.